Into pharma's roaring twenties

“I drained the last of my cocktail, gazing up at the ceiling. It was one of those moments that curls the hairs on your neck. At once, the grand scale of this labyrinth of cathedrals became clear, the desert wind blowing through the clever hieroglyphics carved into every available surface. I turned my head back down to ground level just in time to see the man draw back his fist in anger, and then.And then.With a piercing shriek, he lunged straight at my jaw –”Do you ever wake from a dream, marvelling at the inventiveness and detail of your subconscious mind? That disorienting moment where you lie blinking in darkness, for a second believing it really did happen. Suddenly you admire your own creative abilities in conjure up such a rich and immersive world.It felt so real.It ’s time to summon that subconscious creativity more readily. In the 2020s, such storytelling skills will be vital in finding and communicating a purpose. This skill will separate the winners from the losers. The 2010s: scaling incredible scienceThis past week, I asked twenty pharma and patient friends what they felt was, personally, their biggest moment of the 2010s – and their likely biggest of the next decade.For the decade just passed, the undoubted top choice was the ability to personalise medicine, with nearly two-thirds of respondents citing gene editing as the most impactful development.Simon Davies (Exec Director, Teen Cancer America) shared the moving story of Emil...
Source: EyeForPharma - Category: Pharmaceuticals Authors: Source Type: news

Related Links:

Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part BAuthor(s): Yanhua Liu, Yang Li, Shanshan Dong, Lu Han, Ruixin Guo, Yourong Fu, Shenghu Zhang, Jianqiu Chen
Source: Journal of Hazardous Materials - Category: Environmental Health Source Type: research
Authors: Musio F Abstract INTRODUCTION: Anemia has and will continue to be a central theme in medicine particularly as clinicians are treating a burgeoning population of complex multi-organ system processes. As a result of multiple randomized controlled trials (RCTs), meta-analyses, and societal recommendations overly restrictive paradigms and under-administration of erythropoiesis stimulating agents (ESAs) have likely been followed by clinicians among all specialties. AREAS COVERED: A review of anemia in the context of chronic kidney disease, hematologic malignancies and cancer is presented with focus on the e...
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research
Publication date: January 2021Source: Urology Case Reports, Volume 34Author(s): Nina Al-Saadi, Safa Al-Musawi, Yousuf Khan, Daben Dawam
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research
Authors: Matti B, Zargar-Shoshtari K Abstract Prostate cancer represents a significant health burden worldwide. The cancer incidence had substantially increased since the introduction of prostate specific antigen (PSA) in cancer screening. This had led to considerable debates among health professionals and epidemiologists, since PSA as a screening tool seemed to be far from perfect. In New Zealand, the controversy was quite prominent in the last three decades, with some advocating the benefits of screening, while others concerned regarding the risk of harms. With the absence of an organised screening programme and ...
Source: New Zealand Medical Journal - Category: General Medicine Tags: N Z Med J Source Type: research
CONCLUSION: The proposed PHARMAC criteria will give access to these important drugs to those people with T2DM who will likely benefit the most. PMID: 33032305 [PubMed - in process]
Source: New Zealand Medical Journal - Category: General Medicine Tags: N Z Med J Source Type: research
CONCLUSION: This study found that childhood cancer survivors in New Zealand had a high prevalence of developmental dental abnormalities and it identified potential risk factors related to their cancer treatment. Inequitable access to oral rehabilitation for this patient group argues for a mechanism for consistent improved access to publicly funded dental care across district health boards in New Zealand. PMID: 33032302 [PubMed - in process]
Source: New Zealand Medical Journal - Category: General Medicine Tags: N Z Med J Source Type: research
Authors: Zarrabi A, Mark S PMID: 33032299 [PubMed - in process]
Source: New Zealand Medical Journal - Category: General Medicine Tags: N Z Med J Source Type: research
Authors: Peng C, Cohen DJ Abstract INTRODUCTION: Esophageal squamous cancer remains an important cause of mortality worldwide with two new immunotherapy drugs recently approved for metastatic disease. AREAS COVERED: The authors review the epidemiology and genomics of esophageal squamous cell carcinoma. They also examine prior trials involving targeted agents under investigation as well immunotherapies that have been approved and novel combinations. EXPERT OPINION: Great advances have been made in characterizing the molecular changes in esophageal carcinoma. However, relatively few drugs have shown benefit i...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
This article summarizes the rationale for, and development of CDK inhibitors in melanoma, with their evolution from pan-CDK inhibitors to highly specific agents, throughout clinical trials and finally their potential future use. EXPERT OPINION: Whilst CDK inhibitors have been practice changing in breast cancer management, their efficacy is yet to be proven in melanoma. Combination with BRAF/MEK inhibitors has been hindered by dose-limiting toxicities, but their role may yet to be found within the spectrum of biomarker-derived personalized melanoma management. The effect that CDK inhibitors can have as an adjunct to imm...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
More News: Accidents | Alzheimer's | American Health | Cancer | Cancer & Oncology | Cancer Vaccines | Cervical Cancer | Child Development | Children | Clinical Trials | Diabetes | Diabetes Type 2 | Disability | Electronic Health Records (EHR) | Endocrinology | Esophagus Cancer | Gene Therapy | Genetics | Hives | Hospitals | Infectious Diseases | Laryngeal Cancer | Legislation | Leukemia | Medical Ethics | Men | Merck | Partnerships | Pharmaceuticals | Politics | Rare Diseases | Science | Stem Cell Therapy | Stem Cells | Superbugs | Toxicology | Vaccines | Vitamins